VERV
Verve Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 3
consensus rating "Strong Buy"
Revenue Beats Expectation
Price Hits New Low
Price Hits 52-week low
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About VERV
Verve Therapeutics, Inc.
A clinical-stage biotech company pioneering gene editing therapies for cardiovascular diseases
201 Brookline Avenue
, Suite 601
, Boston
, Massachusetts 02215
--
Verve Therapeutics, Inc., was incorporated as a Delaware corporation on March 9, 2018. The company is a gene drug company that has pioneered a new approach to treating cardiovascular disease, or CVD, transforming the treatment from chronic management to one-way gene editing drugs. The company believes that a single course of treatment can provide significant health benefits over a lifetime for patients with atherosclerotic cardiovascular disease or ASCVD or at risk of atherosclerotic cardiovascular disease.
Company Financials
EPS
VERV has released its 2024 Q4 earnings. EPS was reported at -0.58, versus the expected -0.67, beating expectations. The chart below visualizes how VERV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VERV has released its 2024 Q4 earnings report, with revenue of 13.08M, reflecting a YoY change of 154.28%, and net profit of -50.04M, showing a YoY change of -3.48%. The Sankey diagram below clearly presents VERV’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
